Robert H.I. Andtbacka

12.5k total citations · 4 hit papers
92 papers, 5.4k citations indexed

About

Robert H.I. Andtbacka is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Robert H.I. Andtbacka has authored 92 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Oncology, 25 papers in Molecular Biology and 23 papers in Immunology. Recurrent topics in Robert H.I. Andtbacka's work include CAR-T cell therapy research (33 papers), Virus-based gene therapy research (22 papers) and Immunotherapy and Immune Responses (21 papers). Robert H.I. Andtbacka is often cited by papers focused on CAR-T cell therapy research (33 papers), Virus-based gene therapy research (22 papers) and Immunotherapy and Immune Responses (21 papers). Robert H.I. Andtbacka collaborates with scholars based in United States, United Kingdom and Spain. Robert H.I. Andtbacka's co-authors include Lisa Chen, Igor Puzanov, Frances A. Collichio, Kevin Gorski, Howard L. Kaufman, Mohammed Milhem, Jennifer Gansert, F. Stephen Hodi, Merrick I. Ross and Russell S. Richardson and has published in prestigious journals such as Cell, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Robert H.I. Andtbacka

87 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

2017 1.1k citations Igor Puzanov, Robert H.I. Andtbacka et al. profile →
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

2017 471 citations Jason Chesney, Igor Puzanov et al. Journal of Clinical Oncology profile →
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

2016 435 citations Igor Puzanov, Mohammed Milhem et al. Journal of Clinical Oncology profile →
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

2021 240 citations Funda Meric‐Bernstam, Randy F. Sweis et al. Clinical Cancer Research profile →

Peers

Countries citing papers authored by Robert H.I. Andtbacka

Since Specialization

Citations

This map shows the geographic impact of Robert H.I. Andtbacka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert H.I. Andtbacka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert H.I. Andtbacka more than expected).

Fields of papers citing papers by Robert H.I. Andtbacka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert H.I. Andtbacka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert H.I. Andtbacka. The network helps show where Robert H.I. Andtbacka may publish in the future.

Co-authorship network of co-authors of Robert H.I. Andtbacka

This figure shows the co-authorship network connecting the top 25 collaborators of Robert H.I. Andtbacka. A scholar is included among the top collaborators of Robert H.I. Andtbacka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert H.I. Andtbacka. Robert H.I. Andtbacka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1006P Phase I dose escalation study of HFB200603, a best-in-class BTLA antagonist monoclonal antibody (mAb), in monotherapy and in combination with the anti-PD-1 mAb tislelizumab (TIS) in adult patients (pts) with advanced solid tumors 2024 ·Annals of Oncology ·M. De Miguel, (unknown), Víctor Moreno, (unknown), Jessica Menis, Giuseppe Daniele, Anthony B. El-Khoueiry, Alexander I. Spira, Alessia Gravina, Anthony J. Olszanski, (unknown), (unknown), (unknown), (unknown), (unknown), William D. Hedrich, (unknown), Jinping Gan, Xiaorong Shi, Robert H.I. Andtbacka	0
2	A phase I monotherapy dose escalation study of HFB301001, a novel next generation OX40 agonist monoclonal antibody, in adult patients with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Anthony B. El-Khoueiry, Elena Garralda, Andrés Cervantes, Candace L. Haddox, Hani M. Babiker, Mitesh J. Borad, Konstantinos Leventakos, Ranee Mehra, Jon Zugazagoitia, Diana L. Hanna, Guzmán Alonso, Angela Liu, Xiaorong Shi, (unknown), (unknown), William D. Hedrich, (unknown), (unknown), (unknown), Robert H.I. Andtbacka	1
3	Phase I dose escalation trial of the first-in-class TNFR2 agonist monoclonal antibody, HFB200301, in monotherapy and in combination with tislelizumab, an anti-PD-1 monoclonal antibody, in adult patients with advanced solid tumors. 2024 ·Journal of Clinical Oncology ·Desamparados Roda, Jon Zugazagoitia, Elena Garralda, Alexander I. Spira, Anthony B. El-Khoueiry, Hani M. Babiker, Peter Oppelt, (unknown), Shaozhen Xie, (unknown), Jinping Gan, (unknown), (unknown), William D. Hedrich, (unknown), (unknown), Robert H.I. Andtbacka	0
4	Abstract 1863: Evaluation of BDB101, a first-in-class TLR7/8 dual agonist conjugated to an anti-PD-L1 mAb, in cancer treatment 2023 ·Cancer Research ·Jing Yang, Robert H.I. Andtbacka, (unknown), Lixin Li	1
5	OrienX010, an oncolytic virus, in patients with unresectable stage IIIC–IV melanoma: a phase Ib study 2022 ·Journal for ImmunoTherapy of Cancer ·Chuanliang Cui, Xuan Wang, Bin Lian, (unknown), Li Zhou, Zhihong Chi, Lu Si, Xinan Sheng, Yan Kong, Jiayi Yu, Siming Li, Lili Mao, Bixia Tang, Jie Dai, Xieqiao Yan, Xue Bai, Robert H.I. Andtbacka, (unknown)	38
6	Mavorixafor, an Orally Bioavailable CXCR4 Antagonist, Increases Immune Cell Infiltration and Inflammatory Status of Tumor Microenvironment in Patients with Melanoma 2022 ·Cancer Research Communications ·Robert H.I. Andtbacka, (unknown), Robert H. Pierce, Jean S. Campbell, Melinda Yushak, Mohammed Milhem, Merrick Ross, (unknown), Robert D. Arbeit, Sudha Parasuraman, Kris Bickley, Cecilia C.S. Yeung, Lauri D. Aicher, Kimberly S. Smythe, Lu Gan	15
7	Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas breakdown → 2021 ·Clinical Cancer Research ·Funda Meric‐Bernstam, Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H.I. Andtbacka, Matthew Ingham, Nancy Lewis, Xinhui Chen, Marc R. Pelletier, Xueying Chen, Jincheng Wu, Thomas W. Dubensky, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Jason J. Luke	240
8	Current strategies for intratumoural immunotherapy – Beyond immune checkpoint inhibition 2021 ·European Journal of Cancer ·Jianda Yuan, Anuradha Khilnani, Joshua Brody, Robert H.I. Andtbacka, Siwen Hu‐Lieskovan, Jason J. Luke, Adi Diab, Aurélien Marabelle, Alexandra Snyder, Z. Alexander Cao, F. Stephen Hodi	39
9	Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma 2019 ·EBioMedicine ·Robert H.I. Andtbacka, Thomas Amatruda, John Nemunaitis, Jonathan S. Zager, John Walker, Jason Chesney, (unknown), Cheng‐Pang Hsu, Cheryl A. Pickett, Janice M. Mehnert	47
10	SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide to modulate SCF- and or KIT-expressing cell functions 2017 ·PLoS ONE ·Lei L. Chen, Jing Zhu, Jonathan A. Schumacher, Chongjuan Wei, Latha Ramdas, Víctor G. Prieto, (unknown), Marco A. De Velasco, Sheryl R. Tripp, Robert H.I. Andtbacka, Launce Gouw, George M. Rodgers, Liansheng Zhang, Benjamin Chan, Pamela B. Cassidy, Robert S. Benjamin, Sancy A. Leachman, Marsha L. Frazier	3
11	Subgroup analysis of a phase II multicenter trial of HF10, oncolytic virus immunotherapy, and ipilimumab combination treatment in unresectable or metastatic melanoma patients 2017 ·Annals of Oncology ·Robert H.I. Andtbacka, Merrick I. Ross, Sanjiv S. Agarwala, Matthew H. Taylor, John T. Vetto, Rogerio I. Neves, Adil Daud, Hung T. Khong, Richard S. Ungerleider, Maki Tanaka, Kenneth F. Grossmann	0
12	Osseointegrated Prosthetic Ear Reconstruction in Cases of Skin Malignancy 2017 ·Annals of Plastic Surgery ·Cori Agarwal, (unknown), (unknown), Robert H.I. Andtbacka	3
13	Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma breakdown → 2016 ·Journal of Clinical Oncology ·Igor Puzanov, Mohammed Milhem, David R. Minor, Omid Hamid, Li Ai, Lisa Chen, Michael Chastain, Kevin Gorski, Abraham Anderson, Jeffrey Chou, Howard L. Kaufman, Robert H.I. Andtbacka	435
14	Tumor response from phase II study of combination treatment with intratumoral HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab in patients with stage IIIB, IIIC, or IV unresectable or metastatic melanoma 2016 ·Annals of Oncology ·Robert H.I. Andtbacka, Merrick I. Ross, Sanjiv S. Agarwala, Matthew H. Taylor, John T. Vetto, Rogerio I. Neves, Adil Daud, Hung T. Khong, Richard S. Ungerleider, Sophie Van Welden, Maki Tanaka, Kenneth F. Grossmann	3
15	Age-related arterial telomere uncapping and senescence is greater in women compared with men 2015 ·Experimental Gerontology ·Ashley E. Walker, R. Garrett Morgan, Stephen J. Ives, Richard Cawthon, Robert H.I. Andtbacka, Dirk Noyes, Lisa A. Lesniewski, Russell S. Richardson, Anthony J. Donato	15
16	Patterns of failure and predictors of outcome in cutaneous malignant melanoma of the scalp 2013 ·Journal of the American Academy of Dermatology ·(unknown), Christopher J. Anker, Sancy A. Leachman, Robert H.I. Andtbacka, Glen M. Bowen, William T. Sause, Kenneth F. Grossmann, Tawnya L. Bowles, R. Dirk Noyes, Ying J. Hitchcock, Kenneth M. Boucher, Dennis C. Shrieve	22
17	Surgery in soft tissue sarcoma: more conservative in extremities, more extended in the retroperitoneum 2012 ·Expert Review of Anticancer Therapy ·Chiara Colombo, R. Lor Randall, Robert H.I. Andtbacka, Alessandro Gronchi	17
18	α₁‐Adrenergic responsiveness in human skeletal muscle feed arteries: the impact of reducing extracellular pH 2012 ·Experimental Physiology ·Stephen J. Ives, Robert H.I. Andtbacka, R. Dirk Noyes, R. Garrett Morgan, Jayson R. Gifford, Song‐Young Park, J. David Symons, Russell S. Richardson	27
19	Surgical Resection of Gastrointestinal Stromal Tumors After Treatment with Imatinib 2006 ·Annals of Surgical Oncology ·Robert H.I. Andtbacka, Chaan S. Ng, Courtney L. Scaife, Janice N. Cormier, Kelly K. Hunt, Peter W. T. Pisters, Raphael E. Pollock, Robert S. Benjamin, Michael A. Burgess, Lei L. Chen, Jonathan C. Trent, Shreyaskumar Patel, Kevin Raymond, Barry W. Feig	204
20	The value of specialization—is there an outcome difference in the management of fistulas complicating diverticulitis 2001 ·Diseases of the Colon & Rectum ·(unknown), Robert H.I. Andtbacka, Ian Shrier, Paul Belliveau, Judith L. Trudel, Barry Stein, Gordon Gilbert, Carol‐Ann Vasilevsky	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact